Author

Yonghao Zhao

ORCID: 0009-0000-5445-7362

Observed ORCID: 0009-0000-5445-7362

OpenAlex ID: A5100578540

A Novel Dual-Payload ADC Platform Integrating Exatecan and Triptolide to Enhance Antitumor Efficacy and Overcome Resistance

2025 · Pengfei Ren, Menglong Guan, et al. · Molecular Cancer Therapeutics · 13

Abstract 1586: KH815, a novel dual-payload TROP2-directed antibody-drug conjugate, shows potent antitumor efficacy in pre-clinical tumor model

2025 · Yonghao Zhao, Pengfei Ren, et al. · Cancer Research · 8

Abstract 1585: KH815, a novel dual-payload TROP2-directed antibody-drug conjugate, shows potent antitumor efficacy in pre-clinical tumor model

2025 · Yonghao Zhao, Pengfei Ren, et al. · Cancer Research · 6

Advancements in Dual-Load Antibody–Drug Conjugates and Challenges with Quality Analysis

2026 · Xiaojuan Yu, Xiao Ke, et al. · Pharmaceuticals · 1

Abstract 1587: A novel dual-payload HER3-directed antibody-drug conjugate, shows potent antitumor efficacy in HER3-low in vivo tumor models

2025 · Yonghao Zhao, Pengfei Ren, et al. · Cancer Research · 1

Abstract LB193: A novel DLL3-B7H3 bispecific dual-payload ADC, KHN928, demonstrates potent antitumor efficacy in small cell lung cancer

2026 · Lu Qi, Gang Lei, et al. · Cancer Research

Abstract LB024: Preclinical profile and first-in-human study design of KHN922, a novel dual-payload HER3-targeted ADC, for advanced solid tumors

2026 · Lu Qi, Rong Liao, et al. · Cancer Research

Abstract LB333: Synergistic antitumor efficacy and clinical translation of a novel dual-payload TROP2 ADC KH815 in combination with a PD-L1/VEGF bispecific antibody

2026 · Yonghao Zhao, Yiwei Li, et al. · Cancer Research

Supplementary Data from A Novel Dual-Payload ADC Platform Integrating Exatecan and Triptolide to Enhance Antitumor Efficacy and Overcome Resistance

2026 · Pengfei Ren, Menglong Guan, et al.

Data from A Novel Dual-Payload ADC Platform Integrating Exatecan and Triptolide to Enhance Antitumor Efficacy and Overcome Resistance

2026 · Pengfei Ren, Menglong Guan, et al.

503 KH-801, a differentated humanized anti-CD24 antibody, potentiates the effects of immunomodulatory and anti-tumor activity in preclinical cancer models with favorable safety profiles

2023 · Xiao Ke, Yonghao Zhao, et al. · Journal for ImmunoTherapy of Cancer

Works count: 11

Citation count: 29

H-index: 3

I10-index: 1